Nektar Therapeutics (NKTR) Stock Price, Quote & News

Latest News on NKTR

Mar 20, 2025, 6:00 PM EDT - 5 weeks ago

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 12, 2025, 8:00 PM EDT - 6 weeks ago

Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 4:15 PM EDT - 6 weeks ago

Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 6:00 PM EST - 7 weeks ago

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets

Feb 26, 2025, 7:00 AM EST - 2 months ago

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata

Feb 24, 2025, 7:00 AM EST - 2 months ago

Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus

Feb 24, 2025, 7:00 AM EST - 2 months ago

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th

Feb 10, 2025, 7:00 AM EST - 2 months ago

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

Jan 10, 2025, 7:00 AM EST - 3 months ago

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis

$Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting$

Dec 7, 2024, 12:00 PM EST - 5 months ago

Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting

Nov 18, 2024, 3:30 PM EST - 5 months ago

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence

Nov 14, 2024, 9:11 AM EST - 5 months ago

Multiple Catalysts Ahead For Nektar Therapeutics

Nov 8, 2024, 12:21 AM EST - 6 months ago

Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:15 PM EST - 6 months ago

Nektar Therapeutics Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 10:15 AM EST - 6 months ago

Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 6, 2024, 6:00 PM EST - 6 months ago

Nektar Therapeutics to Participate in Upcoming Investor Conferences

Nov 4, 2024, 1:44 PM EST - 6 months ago

Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential

Nov 4, 2024, 8:30 AM EST - 6 months ago

Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama

Oct 31, 2024, 6:00 PM EDT - 6 months ago

Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets

Oct 29, 2024, 9:00 AM EDT - 6 months ago

Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases

Oct 17, 2024, 12:07 PM EDT - 6 months ago

Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia

Sep 25, 2024, 3:30 AM EDT - 7 months ago

Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024

Sep 3, 2024, 9:00 AM EDT - 8 months ago

Nektar Management to Present at Upcoming Investor Conferences

Aug 10, 2024, 9:04 AM EDT - 9 months ago

Nektar Therapeutics (NKTR) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 4:15 PM EDT - 9 months ago

Nektar Therapeutics Reports Second Quarter 2024 Financial Results

Aug 1, 2024, 6:00 PM EDT - 9 months ago

Nektar to Announce Financial Results for the Second Quarter 2024 on Thursday, August 8, 2024, After Close of U.S.-Based Financial Markets

Jun 12, 2024, 9:30 AM EDT - 11 months ago

Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024

May 9, 2024, 10:40 PM EDT - 1 year ago

Nektar Therapeutics, Inc. (NKTR) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:15 PM EDT - 1 year ago

Nektar Therapeutics Reports First Quarter 2024 Financial Results

May 2, 2024, 6:00 PM EDT - 1 year ago

Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets

Apr 24, 2024, 7:00 AM EDT - 1 year ago

Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases

Mar 22, 2024, 2:00 PM EDT - 1 year ago

Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 5, 2024, 9:00 AM EST - 1 year ago

Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata

Mar 4, 2024, 10:54 PM EST - 1 year ago

Nektar Therapeutics (NKTR) Q4 2023 Earnings Call Transcript

Mar 4, 2024, 4:15 PM EST - 1 year ago

Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results

Mar 4, 2024, 8:30 AM EST - 1 year ago

Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX

Feb 27, 2024, 6:00 PM EST - 1 year ago

Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 6:00 PM EST - 1 year ago

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets

Jan 3, 2024, 6:00 PM EST - 1 year ago

Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA

Dec 11, 2023, 6:00 PM EST - 1 year ago

Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting

Nov 7, 2023, 9:11 PM EST - 1 year ago

Nektar Therapeutics (NKTR) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 4:15 PM EST - 1 year ago

Nektar Therapeutics Reports Third Quarter 2023 Financial Results

Oct 31, 2023, 6:00 PM EDT - 1 year ago

Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets

Oct 13, 2023, 8:30 AM EDT - 1 year ago

Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress

Oct 2, 2023, 9:00 AM EDT - 1 year ago

Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy

Sep 27, 2023, 9:00 AM EDT - 1 year ago

Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer

Sep 13, 2023, 9:00 AM EDT - 1 year ago

Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

Sep 6, 2023, 6:00 PM EDT - 1 year ago

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th

Aug 8, 2023, 10:58 PM EDT - 1 year ago

Nektar Therapeutics (NKTR) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 4:15 PM EDT - 1 year ago

Market Cap	144.25M
Revenue (ttm)	98.43M
Net Income (ttm)	-118.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-120.86%
Debt to Equity Ratio	0.00

Volume	3,163,500
Avg Vol	2,384,320
Day's Range	N/A - N/A
Shares Out	186.10M
Stochastic %K	84%
Beta	0.69
Analysts	Strong Sell
Price Target	$4.92